Effect of alirocumab on cataracts in patients with acute coronary syndromes

Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts was influenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence was affected by achieved LDL-C levels. Methods The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin. Incident cataracts were pre-specified events of interest. In multivariable analysis using propensity score-matching on characteristics including cataract risk factors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels achieved with alirocumab. Results Over median follow-up of 2.8 years (interquartile range 2.3 − 3.4), the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1.4%]); hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.74 − 1.20). In patients treated with alirocumab with ≥ 2 LDL-C values < 25 mg/dL (0.65 mmol/L), the incidence of cataracts was 71/4305 (1.6%), versus 60/4305 (1.4%) in propensity score-matched patients from the placebo group (HR 1.10, CI 95% 0.78 − 1.55). In patients treated with alirocumab with ≥ 2 LDL-C values < 15 mg/dL (0.39 mmol/L), the incidence of cataracts was 13/782 (1.7%), versus 36/2346 (1.5%) in matched patients from the placebo group (HR 1.03, CI 95% 0.54 − 1.94). Conclusion Treatment with alirocumab versus placebo, added to statin, did not influence the incidence of cataracts, even when achieved LDL-C levels on alirocumab were very low. Longer follow-up studies might be necessary to exclude the long-term effects on the incidence or progression of cataracts. Trial registration ClinicalTrials.gov Identifier: NCT01663402. Supplementary Information The online version contains supplementary material available at 10.1186/s12886-023-03012-1.


Introduction
Age-related cataract is the most common cause of visual impairment and blindness worldwide [1]. The lens fibers that represent the majority of the volume of the lens have a high cholesterol concentration [2]. The avascular lens grows through life, by accumulating fiber cells surrounded by a very rich cholesterol plasma membrane [3,4]. Hence, concerns have been raised that low levels of low-density lipoprotein cholesterol (LDL-C) may increase the risk of cataracts [5], but clinical trial data have not confirmed this association with statins [6,7]. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are potent cholesterol-lowering drugs with the potential to reduce LDL-C to levels well below those achievable with statins [8]. Their safety profile, and especially the risk of cataracts in patients achieving very low LDL C remains debated [9][10][11][12][13][14][15].
The aim of this analysis is to describe the incidence of cataracts in alirocumab-and placebo-treated patients, and to assess whether patients achieving very low LDL-C levels (< 25 or 15 mg/dL [0.65 mmol/L or 0.39 mmol/L]) on treatment experienced a higher incidence of cataracts than those who did not.

Methods
The ODYSSEY OUTCOMES trial [16,17] (NCT01663402; 08/08/2012; Additional file 1: Appendix) was a randomized, double-blind trial that evaluated the efficacy and safety of alirocumab versus placebo in patients with acute coronary syndrome (ACS) and elevated atherogenic lipoproteins despite high-intensity or maximum-tolerated statin treatment. Patient eligibility criteria are detailed in the Additional file 2: Appendix.
Patients with LDL-C ≥ 70 mg/dL [1.81 mmol/L], non − high-density lipoprotein cholesterol ≥ 100 mg/ dL [2.59 mmol/L], or apolipoprotein B ≥ 80 mg/dL) were randomized (1:1) to receive alirocumab 75 mg subcutaneously every 2 weeks or matching placebo starting 1-12 months after ACS. Randomization, with stratification for country, was performed centrally using an interactive voice-response or web-response system [16,17]. In the alirocumab group, a blinded, protocolspecified, dose-adjustment algorithm was used to maximize the number of participants achieving an LDL-C level of 25-50 mg/dL (0.65 − 1.29 mmol/L). Alirocumab 75 mg could be blindly up-titrated to 150 mg if LDL-C was ≥ 50 mg/dL (1.29 mmol/L). Conversely, in patients on the 150 mg dose, the 75 mg was down-titrated if LDL-C was < 15 mg/dL (0.39 mmol/L) on two consecutive measurements. If the LDL-C level was < 15 mg/dL (0.39 mmol/L) on two consecutive measurements on the 75 mg alirocumab dose, placebo was blindly substituted for alirocumab for the rest of the trial. Both patients and investigators were masked to treatment assignment and lipid concentrations.

Statistical analysis
Cataract-related events (incident cataracts or worsening of pre-existing cataracts) were pre-specified events of special interest. They were assessed prospectively as investigator-reported treatment-emergent adverse effects and grouped under the high-level term cataract conditions from MedDRA coding (see Statistical Analysis Plan [16,17]).
Categorical variables were compared with the chisquare test. If relevant, 2-sided 95% confidence interval (CI) of proportion is displayed (Wilson method). Hazard ratios (HR) and 95% CIs were estimated using a Cox proportional-hazards model. Multivariable analysis was performed using 2 propensity-score − matched cohorts to compare incidence of cataracts according to LDL-C levels in alirocumab-treated patients. Each alirocumab patient with ≥ 2 consecutive LDL-C values < 15 mg/ dL (0.39 mmol/L) was matched with 3 placebo patients paired according to these variables. Each alirocumab patient with ≥ 2 consecutive LDL-C values < 25 mg/dL (0.65 mmol/L) was matched with one placebo-treated patient. Baseline characteristics considered for matching were age, sex, smoking, region, diabetes, glycated hemoglobin A1c, lipoprotein(a), body mass index, percent change in LDL-C from qualifying to baseline, and LDL-C value. The trial was powered for the primary efficacy outcome of major adverse cardiac events but not for safety events. Therefore, the safety analysis presented must be viewed as descriptive only. The follow-up period extended from the first injection of study medication (alirocumab or placebo) until 70 days after the final injection of study medication. All analyses were performed using SAS ® version 9.4, (SAS Institute, Inc., Cary, North Carolina).

Results
A total of 18,924 patients were randomized at 1315 sites in 57 countries; 9462 were assigned to alirocumab and 9462 to placebo (Fig. 1).
Outside of China, patients were randomized between November 2012 and November 2015. In China, 613 patients were randomized between May 2016 and February 2017. At baseline, mean ± SD LDL-C was 92 ± 31 mg/ dL (2.41 ± 0.80). At 12 months after randomization by intention-to-treat analysis, mean LDL-C was 48 mg/dL  (Table 1). Cataracts were reported as serious adverse events in 0.1% of patients in both treatment groups, leading to  A total of 4305 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 25 mg/dL (0.65 mmol/L) and were matched to 4305 patients from the placebo group with similar baseline characteristics (Tables 2 and  3). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 28.3 kg/m 2 , LDL-C 2.1 mmol/L, lipoprotein(a) 28.6 mg/dL, and apolipoprotein A1 131.6 mg/dL. A total of 782 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 15 mg/dL (0.39 mmol/L) and were matched to 2346 patients from the placebo group with similar baseline characteristics (Tables 4 and 5). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 27.3 kg/m 2 , LDL-C 2.0 mmol/L, lipoprotein(a) 18.8 mg/dL, and apolipoprotein A1 129.9 mg/dL.

Discussion
Age-related cataract is the most common cause of visual impairment and blindness worldwide [1]. Cataract development can be induced by oxidative stress. It was  hypothesized that the inhibition of cholesterol biosynthesis by statin medications (by a bidirectional effect on oxidation processes) can prevent proper epithelial cell development within the crystalline lens [4].
Administration of atorvastatin was noted to induce cataract in animal models [18]. Clinical trials of statins have yielded inconsistent findings regarding their effects on the risk of cataract. The HOPE-3 trial showed an increase of cataract surgery in patients treated with 10 mg rosuvastatin per day [19]. However, other sub-studies in patients achieving very low LDL-C did not find a correlation between very low LDL-C and cataract development [20,21].
PCSK9 inhibitors are potent cholesterol-lowering drugs. They can reduce LDL-C to levels well below those achievable with statin therapy. The role of very low LDL-C levels in the onset of cataracts remains debated [9]. A pooled analysis of data from alirocumab trials showed that the incidence of cataracts was higher in patients with very low LDL C levels [14]. Other studies have not shown association of very low LDL-C levels achieved with statins and incidence of cataracts [21,22], but did not use a propensity score or other approaches to match patients who achieved very low LDL-C with patients on statin treatment with patients from the corresponding control groups with similar baseline characteristics.
The present analysis demonstrates no overall increased risk of incident cataract with alirocumab versus placebo. Moreover, in analyses limited in the alirocumab group to patients who achieved very low levels of LDL-C, there was no evidence of an increased risk of cataract compared to patients from the placebo group with matched baseline characteristics including established cataract risk factors of age, smoking, diabetes, glycated hemoglobin A1c, and body mass index [9]. The analysis therefore adds to the evidence refuting an increased risk of cataracts in patients with very low LDL-C levels on lipidlowering therapies.

Strengths and limitations
This study involved a large, international clinical trial population with a high prevalence of cataract risk factors and clearly demonstrates the absence of risk of cataracts in patients treated with alirocumab. Moreover, to demonstrate the safety of very low LDL-C levels, propensity score-matching was used to assess a potential relationship of achieved LDL-C to risk of cataract [14,23]. However, it should be stated that the analyses pertaining to very low achieved LDL-C levels did not account for certain cataract risk factors that were not ascertained in the trial, including socioeconomic status, malnutrition, large retinal drusen, prior ocular injury, and radiation exposure [1]. No systematic ophthalmoscopic examination was performed in the trial, and the presence of cataract was determined by clinical visual impairment or non-systematic ophthalmologic examination leading to a diagnosis. It is therefore likely that subclinical cataracts remained undiagnosed in the study population. Moreover, cataracts develop slowly, and the duration of exposure to alirocumab and resulting low LDL-C levels in ODYSSEY OUTCOMES may be too short to exclude a long-term effect on incidence or progression of cataracts. On the other hand, the study cohort had a high prevalence of cataract risk factors including smoking and diabetes and a substantial number of incident cataracts were identified. Lastly, even with the use of propensity score matching, an analysis based on a postrandomization variable such as achieved LDL-C should be considered exploratory.

Conclusions
There was no increase in the incidence of cataract between patients receiving alirocumab or placebo. Moreover, very low achieved LDL-C levels on alirocumab treatment did not appear to increase the risk of cataracts in comparison to patients from the placebo group with similar baseline characteristics including established cataract risk factors. These results indicate that PCSK9 inhibition and resulting low LDL-C levels do not appear to modify the incidence of cataract over a median observation period of 2.8 years. Longer-term evaluation is indicated to add certainty to this conclusion.